Fig. 3From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyThe best change in target lesion diameter from baseline (full analysis set, N = 30)Back to article page